The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure

European Journal of Heart Failure

Volumn 8, Issue 4, 2006, Pages 366-372

  Genth Zotz, Sabine ^a,b   von Haehling, Stephan ^a,c   Bolger, Aidan P ^a   Kalra, Paul R ^a   Wensel, Roland ^a   Coats, Andrew J S ^a   Volk, Hans Dieter ^d   Anker, Stefan D ^a,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

CD14 antibody; CHF; Immunactivation; TNF inhibition

Indexed keywords

CD14 ANTIBODY; CD14 ANTIGEN; ENDOTOXIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IC14; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR DENSITY; SCANNING ELECTRON MICROSCOPY;

AGED; ANTIGENS, CD14; CARDIAC OUTPUT, LOW; ENDOTOXINS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33744814385     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.10.010     Document Type: Article

References (30)

1. Anker S.D., Egerer K.R., Volk H., Kox W.J., Poole-Wilson P.A., and Coats A.J. Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79 (1997) 1426-1430
2. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure. An overview. Heart 90 (2004) 464-470
3. Rauchhaus M., Doehner W., Francis D.P., Davos C., Kemp M., Liebenthal C., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000) 3060-3067
4. Deswal A., Petersen N.J., Feldman A.M., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
5. Baumgarten G., Knuefermann P., and Mann D.L. Cytokines as emerging targets in the treatment of heart failure. Trends Cardiovasc Med 10 (2000) 216-223
6. von Haehling S., and Anker S.D. Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs 14 (2005) 163-176
7. Ulevitch R.J., and Tobias P.S. Receptor-dependent mechanism of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13 (1995) 437
8. Baumgarten G., Knuefermann P., Nozaki N., Sivasubramanian N., Mann D.L., and Vallejo J.G. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of Toll-like receptor-4. J Infect Dis 183 (2001) 1617-1624
9. Underhill D.M., and Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14 (2002) 103-110
10. Schroeder R.A., delaTorre A., and Kuo P.C. CD14-dependent mechanism for endotoxin-mediated nitric oxide synthesis in murine macrophages. Am J Physiol 273 (1997) C1030-C1039
11. Schimke J., Mathison J., Morgiewicz J., and Ulevitch R.J. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci U S A 95 (1998) 13875-13880
12. Leturcq D.J., Moriarty A.M., Talbott G., Winn R.K., Martin T.R., and Ulevitch R.J. Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 98 (1996) 1533-1538
13. Verbon A., Dekkers P.E.P., ten Hove T., Hack C.E., Pribble J.P., Turner T., et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory response in humans. J Immunol 166 (2001) 3599-3605
14. Anker S.D., Ponikowski P., Varney, Chua T.P., Clark A.L., Webb-Peploe K.M., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997) 1050-1053
15. Stordeur P., Poulin L.F., Craciun L., Zhou L., Schandene L., de Lavareille A., et al. Cytokine mRNA quantification by real-time PCR. J Immunol Methods 259 (2001) 55-64
16. Haziot A., Ferrero E., Kontgen F., Hijiya N., Yamamoto S., Silver J., et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 4 (1996) 407-414
17. Frevert C.W., Matute-Bello G., Skerrett S.J., Goodman R.B., Kajikawa O., Sittipunt C., et al. Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol 164 (2000) 5439-5445
18. Knuefermann P., Nemoto S., Misra A., Nozaki N., Defreitas G., Goyert S.M., et al. CD14-deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation 106 (2002) 2608-2615
19. Mann D.L., Mc Murray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
20. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
21. Akashi S., Ogata H., Kirikae F., Kirikae T., Kawasaki T., Nishijima M., et al. Regulatory roles for CD14 and phosphatidylinositol in the signaling via Toll-like receptor 4-MD-2. Biochem Biophys Res Commun 268 (2000) 172-177
22. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., and Adams J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47 (2000) 185-201
23. Conraads V.M., Jorens P.G., De Clerck L.S., Van Saene H.K., Ieven M.M., Bosmans J.M., et al. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 6 (2004) 483-491
24. De Werra I., Zanetti G., Jaccard C., Chiolero R., Schaller M.D., Yersin B., et al. CD14 expression on monocytes and TNFα production in patients with septic shock, cardiogenic shock or bacterial pneumonia. Swiss Med WKLY 131 (2001) 35-40
25. von Haehling S., Genth-Zotz S., Bolger A.P., Kalra P.R., Kemp M., Adcock I.M., et al. Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors. Am J Cardiol 6 95 (2005) 859-885
26. Anker S.D., Ponikowski P.P., Clark A.L., Leyva F., Rauchhaus M., Kemp M., et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 20 (1999) 683-693
27. Kitchens R.L., Thompson P.A., Viriyakosol S., O'Keefe G.E., and Munford R.S. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 108 (2001) 485-493
28. Perera P.Y., Vogel S.N., Detore G.R., Haziot A., and Goyert S.M. CD14-dependent and CD14-independent signaling pathway pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. J Immunol 158 (1997) 4422-4429
29. Gullestad L., Aass H., Fjeld J.G., Wikeby L., Andreassen A.K., Ihlen H., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 (2001) 220-225
30. Fichtlscherer S., Rossig L., Breuer S., Vasa M., Dimmeler S., and Zeiher A.M. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104 (2001) 3023-3025